Literature DB >> 3378226

Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.

J I Sage1, M H Mark.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3378226     DOI： 10.1097/00002826-198804000-00009

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  9 in total

1.  A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.

Authors:  J M Cedarbaum; M Hoey; F H McDowell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

2.  International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease.

Authors:  E C Wolters; H J Tesselaar
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

Review 3.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

Review 4.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 5.  Diagnosis and treatment of Parkinson's disease in the elderly.

Authors:  J I Sage; M H Mark
Journal:  J Gen Intern Med       Date:  1994-10       Impact factor: 5.128

6.  Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.

Authors:  S G Bowes; R J Dobbs; M Henley; A Charlett; C J O'Neill; P W Nicholson; A G Purkiss; C Weller; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.

Authors:  Cheryl H Waters; Paul Nausieda; Lyudmila Dzyak; Joerg Spiegel; Monika Rudzinska; Dee E Silver; Elena S Tsurkalenko; Sherron Kell; Ann Hsu; Sarita Khanna; Suneel Gupta
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

8.  Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations.

Authors:  John C Morgan; Rohit Dhall; Robert Rubens; Sarita Khanna; Suneel Gupta
Journal:  Parkinsons Dis       Date:  2018-10-22

Review 9.  Levodopa in Parkinson's Disease: Current Status and Future Developments.

Authors:  Nicola Tambasco; Michele Romoli; Paolo Calabresi
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.